Form 4 for VRXA Veraxa Biotech AG - Post de-SPAC
Accepted 2026-08-31 16:10:06 ET · period of report 2026-08-27 · accession 0001829126-26-009543 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 16:10 | 2026-08-27 | VRXA | Antz Christoph Rudiger | CEO, Dir | P - Purchase | $1.53 | +5,000 | 5,000 | New | +$7,650 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-08-27 | P | A | 5,000 | $1.53 | 5,000 | D | — | — |